Share on StockTwits

Pure Bioscience (NASDAQ:PURE) Director William Otis bought 20,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The stock was purchased at an average cost of $0.85 per share, for a total transaction of $17,000.00. Following the purchase, the director now directly owns 220,000 shares of the company’s stock, valued at approximately $187,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Separately, analysts at Zacks reiterated an “outperform” rating on shares of Pure Bioscience in a research note on Tuesday, June 10th. They now have a $3.00 price target on the stock.

Pure Bioscience (NASDAQ:PURE) remained flat at $1.01 during trading on Thursday. Pure Bioscience has a 1-year low of $0.45 and a 1-year high of $1.70. The stock has a 50-day moving average of $1.04 and a 200-day moving average of $1.19. The company’s market cap is $29.3 million.

Pure Bioscience (NASDAQ:PURE) last announced its earnings results on Tuesday, June 10th. The company reported ($0.07) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.05) by $0.02. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million.

PURE Bioscience is engaged in the development and commercialization of bioscience technologies. The Company’s flagship bioscience technology is a aqueous antimicrobial called silver dihydrogen citrate (NASDAQ:PURE).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.